Analysis reveals comparable PSA responses in metastatic hormone-sensitive prostate cancer, indicating therapy choice impact.
In this real-world Japanese cohort, Enz and Apa plus ADT showed comparable PSA responses, TTCR, and OS after PSM; however, Apa was associated with shorter TTF and more frequent AE-related treatment discontinuation. Reduced-dose initiation was more common with Apa without apparent TTCR disadvantage. Given the limited number of events, these findings should be interpreted with caution.
No takes yet. Share an insight, caveat, or question.
Nishimura et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: